rs3754777 — STK39

STK39 — The Kidney Kinase That Tips Blood Pressure

Inside the kidney's distal tubule, a molecular switch determines how much sodium your body reclaims from the urine and how much it lets go. That switch is SPAK kinase¹¹ SPAK kinase
STE20/SPS1-related proline/alanine-rich kinase, encoded by STK39, and the rs3754777 variant in its gene quietly dials up its activity — with measurable consequences for blood pressure.

STK39 sits within a pathway that controls two sodium transporters in kidney tubule cells: NCC²² NCC
the sodium-chloride cotransporter (SLC12A3), the target of thiazide diuretics and NKCC2 (the sodium-potassium- chloride cotransporter). SPAK phosphorylates and activates both. More SPAK activity means more sodium pulled back into the bloodstream — and higher blood pressure.

The Mechanism

rs3754777 lies in intron 5 of STK39, on the minus strand of chromosome 2 (GRCh38 chr2:168159404). The variant is intronic and does not alter the SPAK protein sequence directly. Its effect is regulatory: the T allele increases STK39 mRNA expression relative to the C allele. In a 2015 study by Mandai et al.³³ Mandai et al.
CRISPR knockin cell lines carrying the hypertension-associated allele, homozygous T/T knockin cells showed elevated total SPAK protein, increased phosphorylated SPAK, and — critically — enhanced phosphorylation of NCC and NKCC1 compared to wild-type cells. The effect was dose-dependent: heterozygous cells showed an intermediate increase. More phosphorylated NCC means more active sodium reabsorption in the distal nephron, which raises circulating blood volume and blood pressure.

This mechanism is pharmacologically important. Thiazide diuretics such as hydrochlorothiazide⁴⁴ Thiazide diuretics such as hydrochlorothiazide
drugs that block NCC directly, the immediate downstream target of SPAK are first-line antihypertensives. If SPAK activity is constitutively elevated by the T allele, there is more NCC to block — but the clinical data suggest the opposite effect: T allele carriers show reduced blood pressure response to hydrochlorothiazide, possibly because compensatory upregulation of NKCC2 or other pathways partially bypasses NCC blockade.

The Evidence

The strongest population-level evidence comes from a meta-analysis by Xi et al.⁵⁵ meta-analysis by Xi et al.
10 studies, 21,863 hypertensive cases and 24,480 controls across multiple ethnicities. The T allele carried a pooled odds ratio of 1.10 for hypertension (95% CI 1.06–1.15, p=7.95×10⁻⁶). The effect was consistent in Europeans (OR 1.08) and East Asians (OR 1.16), but not significant in Africans — an ancestry-stratified pattern that has been replicated in several replication cohorts.

The strongest single-cohort estimate comes from the BELHYPGEN study⁶⁶ BELHYPGEN study
779 hypertensive patients and 906 normotensive controls, all Caucasian, recruited across 6 Belgian academic centers. The TT genotype appeared in 7.3% of hypertensives versus 3.0% of controls (adjusted OR 5.9, 95% CI 2.2–15.6). Carriers of the TT genotype had systolic blood pressure averaging 10 mmHg higher than CC homozygotes (140.1 vs 130.4 mmHg, p=0.002). A cumulative risk score combining STK39 and WNK1 (a kinase upstream of SPAK) showed a dose-response relationship, with systolic BP rising from 129.8 to 149.3 mmHg across zero to two risk genotypes.

The evidence is not unanimous. A 2009 British Caucasian family study found no significant blood pressure association, and a second meta-analysis (Yang et al. 2016) reported high heterogeneity (I² >80%) and did not find rs3754777 significant in pooled analysis, though it identified smoking as a significant modifier (p=0.017). The evidence level is therefore rated moderate: the biological mechanism is functionally validated, the epidemiological signal is replicated but inconsistent, and the effect size in unselected populations is modest.

Practical Actions

For the minority of individuals carrying the TT genotype, the signal is clearest: elevated SPAK-driven sodium retention is the likely mechanism. Blood pressure monitoring and dietary sodium restriction are genotype-specific actions because the SPAK pathway is particularly sensitive to sodium load. For CT heterozygotes, the risk is intermediate and the practical threshold for action is higher.

Thiazide diuretic response data add a pharmacogenomics dimension: T allele carriers responded less well to hydrochlorothiazide in a Chinese hypertension cohort. If blood pressure management is needed, this finding supports discussing alternative antihypertensive strategies — particularly WNK-SPAK pathway inhibitors that are now in clinical development, or calcium channel blockers that bypass the sodium cotransporter axis entirely.

Interactions

STK39/SPAK operates immediately downstream of the WNK kinases (WNK1, WNK4), which sense intracellular chloride and activate SPAK under low-chloride conditions. rs1468326 in WNK1 has been associated with hypertension in the same BELHYPGEN cohort where rs3754777 showed the clearest effect, and the two risk genotypes showed additive effects on systolic blood pressure. This STK39–WNK1 interaction is a strong candidate for a compound action: carriers of both risk genotypes may warrant earlier blood pressure monitoring than either allele alone predicts.